Mirae Asset Global Investments Co. Ltd. Buys New Stake in Gilead Sciences, Inc. $GILD

Posted by Geri Gentry on Nov 1st, 2026

Gilead Sciences logo Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,050,244 shares of the biopharmaceutical company’s stock, valued at approximately $156,539,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Investment Partners LTD. raised its position in shares of Gilead Sciences by 5.4% during the 3rd quarter. Investment Partners LTD. now owns 4,084 shares of the biopharmaceutical company’s stock worth $609,000 after buying an additional 211 shares in the last quarter. Blue Fin Capital Inc. acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $201,000. Summit Global Investments lifted its stake in shares of Gilead Sciences by 41.3% in the 3rd quarter. Summit Global Investments now owns 16,549 shares of the biopharmaceutical company’s stock worth $2,467,000 after acquiring an additional 4,837 shares during the period. MGO One Seven LLC lifted its stake in shares of Gilead Sciences by 31.0% in the 3rd quarter. MGO One Seven LLC now owns 17,858 shares of the biopharmaceutical company’s stock worth $2,662,000 after acquiring an additional 4,231 shares during the period. Finally, Americana Partners LLC bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $369,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $170.68 on Friday. Gilead Sciences, Inc. has a twelve month low of $114.02 and a twelve month high of $175.65. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The company has a 50-day moving average of $150.87 and a 200-day moving average of $139.79. The firm has a market cap of $211.63 billion, a price-to-earnings ratio of -54.01 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.70%. The company had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter in the previous year, the company posted $2.47 EPS. The business’s revenue was up 6.8% compared to the same quarter last year. Analysts forecast that Gilead Sciences, Inc. will post -1.03 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 annualized dividend and a yield of 1.9%. Gilead Sciences’s payout ratio is -103.80%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew Dickinson sold 3,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the transaction, the chief financial officer owned 161,096 shares of the company’s stock, valued at approximately $25,166,417.12. This represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director owned 12,894 shares of the company’s stock, valued at $1,916,306.28. This trade represents a 58.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock valued at $15,877,860 in the last 90 days. 0.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a report on Friday. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Citigroup increased their price target on Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a research note on Friday. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $184.00 price target on shares of Gilead Sciences in a research report on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $169.19.

Check Out Our Latest Analysis on GILD

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.